Systemic concentrations of salbutamol and HFA-134a after inhalation of salbutamol sulfate in a chlorofluorocarbon-free system

Therapeutic Drug Monitoring

Volumn 18, Issue 3, 1996, Pages 240-244

  Harrison, Lester I ^a   Cline, Ann ^a   Wells, Teresa M ^a   Jacobson, Joseph P ^a   Cooper, Katherine M ^a   Chang, Shaw F ^a   Nelson, Janyce R ^a   Ekholm, Bruce P ^a   Morganroth, Joel ^b  

^a 3M COMPANY   (United States)

^b Research Data Worldwide   (United States)

Author keywords

Chlorofluorocarbon free; HFA 134a; Metered dose inhaler; Salbutamol

Indexed keywords

CHLOROFLUOROCARBON; SALBUTAMOL; SALBUTAMOL SULFATE; TETRAFLUOROETHYLENE;

ADULT; AEROSOL; ARTICLE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG MONITORING; HUMAN; HUMAN EXPERIMENT; INHALATIONAL DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; AEROSOL PROPELLANTS; ALBUTEROL; CHLOROFLUOROCARBONS, METHANE; HUMANS; HYDROCARBONS, FLUORINATED; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS;

EID: 0029895854     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199606000-00004     Document Type: Article

References (21)

1. Molina MJ, Rowland FS. Stratospheric sink for chlorofluoromethanes: chlorine atom-catalised destruction of ozone. Nature 1974;249:810-2.
2. Manzer LE. The CFC-ozone issue: progress on the development of alternatives to CFCs. Science 1990;249:31-5.
3. Newman SP. Metered dose pressurized aerosols and the ozone layer. Eur Respir J 1990;3:495-7.
4. Kontny MJ, Destefano G, Jager PD, McNamara DP, Turi JS, Van Campen L. Issues surrounding MDI formulation development with non-CFC propellants. J Aerosol Med 1991;4:181-7.
5. Alexander DJ. Safety of propellants. J Aerosol Med 1995; 8(suppl 1):S29-S34.
6. Tansey IP. Challenges in the development of metered dose inhalation aerosols using ozone-friendly propellants. Spray Technol Marketing 1994;4:26-9.
7. Smith IJ. Challenge of reformulation. J Aerosol Med 1995; 8(suppl 1):S19-S27.
8. Donnell D, Harrison LI, Ward S, et al. Acute safety of the CFC-free propellant HFA-134a from a pressurized metered dose inhaler. Eur J Clin Pharmacol 1995 48:473-7.
9. Bleecker ER, Klinger NM, Eckholm BP, Tinkelman DG. Twelve week efficacy and safety comparison of salbutamol formulated with HFA-134a and standard CFC metered dose inhaler devices. Am J Respir Crit Care Med 1995;151:A58.
10. EMM T, Lesko LJ, Leslie J. Determination of albuterol in human serum by reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr 1988;427:188-94.
11. Hutchings MJ, Paull JD, Morgan DJ. Determination of salbutamol in plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1983;277:423-6.
12. Cooper KM, Chang SF, Harrison LI. Determination of the chlorofluorocarbon substitute 1,1,1,2-tetrafluoroethane (HFA-134a) in human and animal blood using gas chromatography with headspace analysis. J Chromatogr 1995; 667:85-93.
13. Stemmann EA, Wolff GE. Salbutamol (aerosol und zafchen) bei kindern mit asthma bronchiale. Monatsschr Kinderheilkd 1980;128:89-92.
14. 2-adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered dose inhaler and modified actuator device. Br J Clin Pharmacol 1993; 36:445-50.
15. Janson C. Plasma levels and effects of salbutamol after inhaled or IV administration in stable asthma. Eur Respir J 1911;4:544-50.
16. Lewis LD, McLaren M, Essex E, Cochrane GM. Plasma concentrations of salbutamol in acute severe asthmatics. Aust NZ J Med 1990;20:204-7.
17. Vaisman N, Koren G, Goldstein D, et al. Pharmacokinetics of inhaled salbutamol in patients with cystic fibrosis versus healthy young adults. J Pediatr 1987;111:914-7.
18. Walters EH, Cockroft A, Griffiths T, Rocchiccioli K, Davies BH. Optimal dose of salbutamol respiratory solution: comparison of three doses with plasma levels. Thorax 1981; 36:625-8.
19. Lin RY, Smith AJ, Hergenroeder P. High serum albuterol levels and tachycardia in adult asthmatics treated with high-dose continuously aerosolized albuterol. Chest 1993; 103:221-5.
20. Schuh S, Parkin P, Rajan A, et al. High- versus low-dose, frequently administered, nebulized albuterol in children with severe, acute asthma. Pediatrics 1989;83:513-8.
21. Swedish Society of Chest Medicine. High-dose inhaled versus intravenous salbutamol combined with theophylline in severe acute asthma. Eur Respir J 1990;3:163-70.